P0064 

P0064 is a selective inhibitor targeting the PR domain of PRDM16. P0064 selectively reduces proliferation and survival of FLT3-ITD+ leukemia cells and induces cell apoptosis. P0064 is promising for research of acute myeloid leukemia (AML)^[1].

P0064 (50 μM) significantly reduces the levels of key phosphorylated proteins in the FLT3 signaling pathway and induces apoptosis in primary FLT3-ITD AML cells, as well as inhibits colony formation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P0064 (100 mg/kg, i.p., once daily, for 4 weeks) combined with Gilteritinib (HY-12432) can minimize the number of human leukemia cells in the mouse bone marrow to the greatest extent^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

326.26

C₁₅H₁₀N₄O₅

299443-19-9

Solid

Yellow to brown

O=C(C1=C(O)C=CC=C1)N/N=C(C2=C(N3)C=CC([N+]([O-])=O)=C2)\C3=O

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Zhai F, et al. PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression. Cancer Res. 2025 Feb 1;85(3):535-550.  [Content Brief]